TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. More pipelines proposed to carry Marcellus gas to southeast markets
  2. Regulators release details of Highmark’s post-UPMC transition plan
  3. Visual search  still hampered  by image issues
  4. Students walk shop class path to excellence
  5. Healthy PA expands number of recipients but cuts benefits
  6. Hershey unwraps new corporate logo
  7. Young adults drive home rental trend in Western Pennsylvania
  8. DQE Communication inks data deal with Iron Mountain
  9. Customers anxious for details about Highmark transition plan for W. Pa.
  10. States clear way for startups to use crowdfunding
  11. Government approves compromise on Corbett’s alternative Medicaid plan
Subscribe today! Click here for our subscription offers.